BioSpace News Archive

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority review the company’s supplemental Biologics License Application (sBLA) for ULTOMIRIS® (ravulizumab-cwvz), the company’s long-acting C5 complement inhibitor, for the treatment of people with atypical hemolytic uremic syndrome (aHUS) in order to inhibit complement-mediated thrombotic microangiopathy (TMA).

Syntrix Pharmaceuticals today announced that it has dosed the first patient in its Phase 1/2 clinical trial that will combine SX-682 with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy. SX-682 is an oral dual inhibitor of CXCR1 and CXCR2 (CXCR1/2) being developed for the treatment of cancer.

Data-driven industry framework is key to measuring healthcare impact and generating strong returns

On November 15th, 2019, expectant parents and healthcare professionals are invited to participate in World Cord Blood Day events being held online and around the globe to celebrate over 30 years of life-saving cord blood transplants and learn about innovative research in the field.

The Supportive Care Coalition and the California State University Institute for Palliative Care have joined forces in a powerful collaboration designed to help Coalition members build the skills and expertise they need to strengthen their palliative care programs and services, and more effectively support seriously ill patients and their families.

Company plans cultivation and processing facility in San Juan area and six dispensaries throughout island

Loopback Analytics, a leading provider of data-driven solutions for hospital and health systems, announced it has partnered with UC Davis Health specialty pharmacy services to help advance patient care and outcomes.

Spectrum Plastics Group, the market leading medical components and contract manufacturer, is pleased to announce the acquisition of Earnan Biomedical Ltd of Wexford, Ireland

IASO Biotherapeutics unveils an innovative new CAR-T therapy for the treatment of relapse/refractory multiple myeloma and the retreatment of previously infused CAR-T patients

The Michael J. Fox Foundation for Parkinson’s Research announces that its Chief Executive Officer, Todd Sherer, PhD, will deliver the keynote speech at the prestigious Gordon Research Conference on Parkinson’s Disease on Sunday, June 23, 2019.